|
Name |
Chartarlactam F
|
| Molecular Formula | C23H31NO4 | |
| IUPAC Name* |
(3R,4aS,7R,8R,8aS)-3,4'-dihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-6,7-dihydro-3H-furo[3,2-g]isoindole]-8'-one
|
|
| SMILES |
C[C@@H]1CC[C@@H]2[C@@]([C@@]13CC4=C(C=C5CNC(=O)C5=C4O3)O)(CC[C@H](C2(C)C)O)C
|
|
| InChI |
InChI=1S/C23H31NO4/c1-12-5-6-16-21(2,3)17(26)7-8-22(16,4)23(12)10-14-15(25)9-13-11-24-20(27)18(13)19(14)28-23/h9,12,16-17,25-26H,5-8,10-11H2,1-4H3,(H,24,27)/t12-,16+,17-,22+,23-/m1/s1
|
|
| InChIKey |
NSKHZIOXIKSFER-NIVYWPPISA-N
|
|
| Synonyms |
Chartarlactam F; CHEMBL3104990
|
|
| CAS | NA | |
| PubChem CID | 73891074 | |
| ChEMBL ID | CHEMBL3104990 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 385.5 | ALogp: | 3.7 |
| HBD: | 3 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 78.8 | Aromatic Rings: | 5 |
| Heavy Atoms: | 28 | QED Weighted: | 0.623 |
| Caco-2 Permeability: | -4.859 | MDCK Permeability: | 0.00000697 |
| Pgp-inhibitor: | 0.012 | Pgp-substrate: | 0.968 |
| Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.143 |
| 30% Bioavailability (F30%): | 0.006 |
| Blood-Brain-Barrier Penetration (BBB): | 0.25 | Plasma Protein Binding (PPB): | 95.91% |
| Volume Distribution (VD): | 1.509 | Fu: | 7.11% |
| CYP1A2-inhibitor: | 0.492 | CYP1A2-substrate: | 0.791 |
| CYP2C19-inhibitor: | 0.282 | CYP2C19-substrate: | 0.314 |
| CYP2C9-inhibitor: | 0.74 | CYP2C9-substrate: | 0.918 |
| CYP2D6-inhibitor: | 0.748 | CYP2D6-substrate: | 0.598 |
| CYP3A4-inhibitor: | 0.257 | CYP3A4-substrate: | 0.228 |
| Clearance (CL): | 10.285 | Half-life (T1/2): | 0.4 |
| hERG Blockers: | 0.058 | Human Hepatotoxicity (H-HT): | 0.481 |
| Drug-inuced Liver Injury (DILI): | 0.035 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.985 | Maximum Recommended Daily Dose: | 0.972 |
| Skin Sensitization: | 0.882 | Carcinogencity: | 0.068 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.37 |
| Respiratory Toxicity: | 0.944 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002996 | ![]() |
1.000 | D0L2LS | ![]() |
0.279 | ||
| ENC003789 | ![]() |
1.000 | D0Z1XD | ![]() |
0.278 | ||
| ENC002673 | ![]() |
0.812 | D0Q6NZ | ![]() |
0.277 | ||
| ENC005396 | ![]() |
0.812 | D03XOC | ![]() |
0.274 | ||
| ENC003020 | ![]() |
0.812 | D08QKJ | ![]() |
0.272 | ||
| ENC003012 | ![]() |
0.773 | D0U3GL | ![]() |
0.266 | ||
| ENC002009 | ![]() |
0.773 | D0I2SD | ![]() |
0.261 | ||
| ENC003552 | ![]() |
0.753 | D04GJN | ![]() |
0.261 | ||
| ENC003008 | ![]() |
0.723 | D09IPV | ![]() |
0.254 | ||
| ENC003014 | ![]() |
0.670 | D08QMX | ![]() |
0.252 | ||